Since the 1980s, the production of monoclonal antibodies using hybridoma cells has been accepted as an effective technology for cancer treatment. Monoclonal antibodies (mAbs) are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens. They have singular activity against a predetermined target and have been shown to be effective in human trials against RSV and Ebola. Today, mAbs make up more than half of the total biopharmaceutical market. That’s why it makes sense that, when the world was thrust into an unprecedented pandemic last year, scientists quickly turned their attention to monoclonal antibodies as a possible treatment for COVID-19. By February 2021, the FDA granted emergency use authorization to three combinations of mAbs to treat mild to moderate COVID-19. Let’s take a look at how they moved this treatment through the drug discovery process in just a few months, in the below infographic.
Please check the highlighted fields and try again.